Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-207P is a pseudogene derived from the U6 small nuclear RNA (snRNA) gene family[2][7]. U6 snRNA itself is a highly conserved and essential component of the spliceosome, the large ribonucleoprotein complex responsible for excising introns from pre-mRNA during splicing[3][5]. However, RNU6-207P does not produce a functional RNA molecule and lacks known biological, pathophysiological, or therapeutic relevance; it instead represents a processed pseudogene resulting from retrotransposition events, often mediated by LINE-1 (Long Interspersed Nuclear Element-1) elements[7][1]. These pseudogenes are abundant in the genome and serve as molecular records of retrotransposition dynamics, but they do not encode protein, do not participate in splicing, and have no established role in disease or as therapeutic targets[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on U6 small nuclear RNA 207, pseudogene (RNU6-207P).